Strongbridge Biopharma plc Announces Presentation at Biotech Showcase 2016
DUBLIN, Ireland and TREVOSE, Pa., Dec. 16, 2015 (GLOBE NEWSWIRE) –Strongbridge Biopharma plc (NASDAQ:SBBP) today announced that management will be presenting at Biotech Showcase 2016 to be held January 11 – 13, 2016 in San Francisco.
Matthew Pauls, president and chief executive officer of Strongbridge Biopharma, is scheduled to present on Monday, January 11, 2016 at 3:00 p.m. PST. The presentation will be webcast live and available on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.
About Strongbridge Biopharma
Strongbridge Biopharma’s strategic focus is to build a biopharmaceutical company focused on the development, in-licensing, acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare diseases. Strongbridge Biopharma’s lead product candidate, COR-003 (levoketoconazole), is a cortisol inhibitor that is currently being studied in the global Phase 3 trial for the treatment of endogenous Cushing’s syndrome. Strongbridge Biopharma recently expanded its rare endocrine disease franchise with the completion of transactions for two Phase 2 product candidates: COR-004, a novel second-generation antisense compound, which is in clinical development for the treatment of acromegaly and designed to block the synthesis of growth hormone receptor (GHr), thereby reducing levels of insulin-like growth factor-1 (IGF-1) in the blood; and COR-005, a next-generation somatostatin analog (SSA) with a unique receptor affinity profile, being investigated for the treatment of acromegaly, with potential additional applications in Cushing’s disease and neuroendocrine tumors. COR-003 and COR-005 have received orphan designation from both the European Medicines Agency and the U.S. Food and Drug Administration, and the Company is pursuing orphan designation for COR-004.Strongbridge Biopharma’s intent is to independently commercialize its rare endocrine assets in key global markets.
Contacts:
Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
lrocco@elixirhealthpr.com
Investor Relations
ICR Inc.
Stephanie Carrington
+1 646-277-1282
Stephanie.Carrington@icrinc.com
USA
900 Northbrook Drive
Suite 200
Trevose, PA 19053
Tel. +1 610-254-9200
Fax. +1 215-355-7389
Source: Strongbridge
